Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnoses of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Eligibility criteria
Qualifiers
Patient with a clinical suspicion for a new diagnosis of AML or MDS for whom the diagnostic molecular testing via the hematologic molecular algorithm (HMA) at BJH is requested or planned to be requested.
Adult patients 18 years or older.
Ability to understand and willingness to sign an IRB approved written informed consent document.
Treating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.
Disqualifiers
Younger than 18 years of age
Does not treat patients at Washington University School of Medicine
Trial design
Treatments tested in this trial
- ChromoSeq
Treatment groups
325 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov